Send us Feedback

Ligand Pharmaceuticals (LGND)
QUOTE AND NEWS
BVF Sells $2.4M Worth of Ligand Pharma
TheStreet.com  Jun 30 
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
Ligand Pharmaceuticals (LGND) Subsidiary Enters Exclusive License Agreement with ParinGenix
StreetInsider.com  Jun 25 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ligand+Pharmaceuticals+%28LGND%29+Subsidiary+Enters+Exclusive+License+Agreement+with+ParinGenix+/4754339.html for the full story.
Ligand Pharma (LGND) Initiates Phase I Trial with LGD-4033
StreetInsider.com  Jun 17 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ligand+Pharma+%28LGND%29+Initiates+Phase+I+Trial+with+LGD-4033/4736925.html for the full story.
Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders
Business Wire  Jun 17 
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor
CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
Business Wire  May 11 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported a correction to its earnings release issued on May 6, 2009 relating to a milestone earned from Pfizer, Inc. Under the terms of a 1991 research agreement with Pfizer and as a result of
Ligand Pharmaceuticals Announces First Quarter Results
Business Wire  May 6 
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced financial results for the first quarter of 2009 and provided an operating forecast and program updates. Financial Results Total revenues from continuing operations for the three months
Ligand to Hold First Quarter Results Conference Call on May 6
Business Wire  Apr 28 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report first quarter 2009 financial results on May 6, 2009, following the close of market. Ligand’s President and CEO, John L. Higgins, Vice President of Finance
Ligand Announces Approval in Europe of CONBRIZA™ for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Business Wire  Apr 27 
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Wyeth (NYSE:WYE) has received approval from the European Commission (EC) for CONBRIZA™ (bazedoxifene), a selective estrogen receptor modulator (SERM) for the
Pfizer Statement on Lasofoxifene
Pharma's Cutting Edge  Sep 13 
This is something you rarely see--Pfizer (or any major) getting a non-approvable letter. I'm particularly surprised to see it tagged to the lasofoxifene submission, because this is a drug that has been in clinical development for many years and is...
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
See All
BULLS: REASONS TO BUY
Bulls: Reasons To Buy
Feeling Bullish? Be the first to explain why this would make a good investment
See All (0)
See All
BEARS: REASONS TO SELL
Bears: Reasons To Sell
Feeling Bearish? Be the first to explain why this would make a poor investment
See All (0)
more ▼EditWIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 
LGND AT A GLANCE
 
 
 
 
 
 
 
 
Please install Flash Player to view this chart.



[edit] References

Retrieved from "http://www.wikinvest.com/stock/Ligand_Pharmaceuticals_(LGND)"
 
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki